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Abstract The MOR-1 gene is large, with a recent study
reporting nine exons spanning 250 kb which combine to yield
six different mu opioid receptor splice variants. We now report
the isolation of exon 10, which is contained within yet another
splice variant, MOR-1F, which is composed of exons 1, 2, 3, 10,
6, 7, 8 and 9. Exon 10 comprises 186 bp which predict a unique
58 amino acid sequence extending beyond exon 3. It has been
mapped between exons 4 and 6 and has flanking consensus splice
sequences. On Northern blot analysis, the MOR-1F mRNA is
smaller than the other MOR-1 mRNAs. When expressed in
CHO cells, MOR-1F binds the mu opioid radioligand
[3H]DAMGO with high affinity (KD = 1.04 þ 0.03 nM). Compe-
tition studies demonstrated the selectivity of the variant for mu
opioid ligands, supporting its classification within the mu opioid
receptor family.
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1. Introduction
Morphine elicits its e¡ects through mu opioid receptors.
Pharmacological studies have implied the presence of mu
opioid receptor subtypes [1]. The antagonists naloxonazone
and naloxonazine suggested the existence of mu1 and mu2
receptors [2^6] while more recent studies have raised the pos-
sibility of a third mu opioid receptor responsible for the ac-
tions of morphine-6L-glucuronide (M6G) and heroin [7^10].
However, only one gene has been identi¢ed which encodes a
mu opioid receptor, MOR-1 [11^14]. Antisense studies quickly
established the importance of MOR-1 in morphine analgesia
in the rat [15]. However, not all antisense probes blocked
morphine analgesia [9,16]. While a series of antisense oligo-
deoxynucleotides targeting exon 1 were active, antisense
probes based upon exon 2 were not. M6G analgesia revealed
a very di¡erent sensitivity pro¢le. The exon 1 antisense probes
active against morphine were ine¡ective against M6G. Con-
versely, the exon 2 antisense oligodeoxynucleotides which
were inactive against morphine potently blocked M6G anal-
gesia. These results raised the possibility that the receptor
responsible for morphine and M6G analgesia might be splice
variants of MOR-1 [9,16]. Two splice variants were reported
soon after the initial description of MOR-1. One variant
lacked exon 4 [17] while a second contained an alternative
exon (exon 5) in place of the original exon 4 [18]. Our group
then identi¢ed an additional four exons downstream from
exon 4 which combine to yield three additional slice variants
[19]. We now report the presence of yet another MOR-1 exon
and a novel MOR-1 splice variant.
2. Materials and methods
Male Crl:CD-1(ICR)BR mice (24^32 g) (Charles River Labs, Ra-
leigh, NC, USA) were maintained on a 12 h light/dark cycle with food
and water available ad libitum. Opiate drugs were provided by the
Research Technology Branch of the National Institute on Drug
Abuse. Halothane was purchased from Halocarbon Laboratory
(Hackensack, NJ, USA).
2.1. RT-PCR cloning and genomic mapping
Mouse brain total RNA was obtained and reverse-transcribed with
Superscript II (GIBCO) (Pan, Xu et al., 1999, ID: 7934). Partial
cDNA sequences of MOR-1F were obtained by a nested PCR ap-
proach using the ¢rst-strand cDNA as template. A sense primer (sense
primer A, 5P-CCC AAC TTC CTC CAC AAT CGA A-3P, which was
designed from the 3P-end of exon 3) and an antisense primer (anti-
sense primer A, 5P-GAA AGG CAT CTA CCC TCT CGC TGT-3P,
which was derived from exon 9; GenBank accession number
AF062752) were used in the ¢rst-round PCR, which did not produce
visible bands on agarose gel. The ¢rst-round PCR product was then
used as template in the second-round PCR with a pair of nested
primers (sense primer B from exon 3, 5P-GGG AAC ACC CCT
CCA CGG C-3P and antisense primer B from exon 9, 5P-CCA CAC
TGC TCA CCA GCT CAT CCC-3P). A new band of approximately
550 bp was puri¢ed from the agarose gel, subcloned into pCRII-
TOPO vector (Invitrogen) and sequenced.
Full-length cDNA clones containing exon 10 were obtained by the
RT-PCR approach. Two sense primers (A, 5P-GAG AGG AAG
AGG CTG GGG CGC-3P and B, 5P-GGA ACC CGA ACA CTC
TTG AGT GCT-3P, both of which were designed from 5P-UTR of
MOR-1) and two antisense primers (antisenses A and B, see above)
were used in the nested PCR with the ¢rst-strand cDNA reverse-tran-
scribed from mouse brain RNA as template. A 1.7 kb fragment was
ampli¢ed and subcloned into pCRII-TOPO vector and sequenced.
Sequence analysis of the product (MOR-1F, GenBank accession num-
ber AF167568) showed that it contained coding exons 1, 2, and 3
from MOR-1 followed by exons 10, 6, 7, 8 and 9. The location of
exon 10 within the MOR-1 gene was mapped in the BAC clone by
long PCR using an AccuTag polymerase (Sigma, St. Louis, MO,
USA).
2.2. Northern blotting analysis
Total RNA was obtained from mouse brain by the guanidinium
thiocyanate phenol-chloroform extraction and Northern analysis per-
formed [19]. In brief, 50 Wg of total brain RNA was loaded, separated
on a 0.8% formaldehyde agarose gel and transferred to a GenePlus
membrane (New England Nuclear Corp, Boston, MA, USA). The
membrane was hybridized with a 32P-labeled exon 10 fragment gen-
erated by PCR with a sense (5P-GCCTGGAGCCAACAGAGGT-
CAAACGAAG-3P) and an antisense primer (5P-GCGGGACCAGA-
GAGATGGCTAGTGG-3P).
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2.3. Regional RT-PCR
Total RNA was isolated from di¡erent mouse brain regions and
reverse-transcribed with Superscript II. The ¢rst-strand cDNA was
ampli¢ed with a sense primer from exon 3 (sense primer A) and an
antisense primer from exon 10 (5P-CTT GCT GCC TTC GTA AGG
ACC TGG G-3P). RNA loading was measured by a parallel PCR with
L2-microglobulin primers (ClonTech). The PCR products were sepa-
rated on a 1% agarose gel, stained with ethidium bromide and photo-
graphed with Kodak DC120 Digital Camera and Imaging System.
2.4. Expression of MOR-1F
The cDNA fragment containing the full-length MOR-1F in pCRII-
TOPO was subcloned into pcDNA3.1 (Invitrogen). The resulting plas-
mid, MOR-1F/pcDNA3 was used to transfect CHO cells by Lipofect-
AMINE reagent (GIBCO, Gaithersburg, MD, USA). Stable trans-
formants were obtained 2 weeks after selection with G418 and
screened in a [3H]DAMGO binding assay. A stable clone, 10-5,
showed high levels of binding (Bmax = 1.69 þ 0.35 pmol/mg protein)
and was selected for further binding studies.
2.5. Receptor binding assays
Membranes were isolated from stable transfected clones and bind-
ing performed with [3H]DAMGO at 25‡C for 1 h in potassium phos-
phate bu¡er (50 mM, pH 7.4) containing magnesium sulfate (5 mM).
Speci¢c binding was de¢ned as the di¡erence between total binding
and non-speci¢c binding remaining in the presence of levallorphan (1
WM). KD and Ki values were calculated by non-linear regression anal-
ysis (Prism, Graphpad Software, San Diego, CA, USA).
2.6. Behavioral testing
The drugs were administered subcutaneously (s.c.), intracerebroven-
tricularly (i.c.v.) [20] or intrathecally (i.t.) [21]. Analgesia was assessed
quantally as a doubling or greater of the baseline latency for the
individual mouse using the radiant heat tail£ick assay, with baselines
ranging between 2^3 s, as previously described [9,22]. A cuto¡ of 10 s
was imposed to minimize tissue damage. Groups were compared with
the Fischer exact test.
3. Results and discussion
To explore for possible additional splice variants of MOR-
1, we performed nested RT-PCR using upstream primers in
exon 3 and downstream primers in exon 9 (Fig. 1). In addition
to the expected three fragments corresponding to MOR-1C,
MOR-1D and MOR-1E, we observed a new band (V550 bp)
which was larger than the predicted three fragments. Sequenc-
ing this band revealed a new 186 bp insertion (Fig. 1B) be-
tween exons 3 and 6. The new nucleotide sequence, exon 10,
was mapped between exons 4 and 6 on a mouse genomic BAC
clone [19] by a long PCR approach using AccuTag polymer-
ase (Fig. 1). Sequence analysis of the BAC clone indicated
that the £anking sequences of exon 10 were consistent with
consensus splice junctions. The full-length cDNA for MOR-
1F contained exons 1, 2, 3, 10, 6, 7, 8 and 9 (Fig. 1).
Northern analysis of the new exon 10 revealed a band of
approximately 4.4 kb, which was signi¢cantly smaller than the
exon 4 probe labeling MOR-1 or the exon 7/8/9 probe which
hybridizes to MOR-1C, MOR-1D and MOR-1E (Fig. 2).
The distribution of MOR-1F mRNA di¡ered across brain
regions as determined by RT-PCR (Fig. 3). The highest levels
appeared to be in the hypothalamus, with moderate levels in
the PAG and thalamus. Although lower levels were seen in
the other regions, MOR-1F mRNA was seen in all of them.
However, the expression of MOR-1F appeared to be restricted
to the brain, with no observable expression in other peripheral
tissues, such as heart, spleen, lung, liver, muscle and testes
(unpublished observations).
Translation of the sequence predicted a novel 58 amino acid
sequence extending beyond the sequence encoded by exon 3.
The termination codon was located within exon 10, with the
downstream exons 6, 7, 8 and 9 all in the 3P-untranslated
region. There was no amino acid sequence overlap between
MOR-1F and the other known MOR-1 variants. The amino
acid sequence encoded by exon 10 was acidic, with a calcu-
lated isoelectric point (pI) of 4.47, a value similar to that of
MOR-1D (4.44) and MOR-1 (3.46), but appreciably lower
Fig. 1. Schematic of the MOR-1 gene and alternative splicing.
A: Exons and introns on MOR-1 are shown by boxes and horizon-
tal lines, respectively. The exons are numbered according to their
discovery. The exon components of the various variants are pre-
sented. Termination codons are present in the following exons for
each variant: MOR-1, 4; MOR-1A, 3; MOR-1B, 5; MOR-1C, 9;
MOR-1D, 9; MOR-1E, 6; MOR-1F, 10. B: The nucleotide sequence
of exon 10 (upper case), along with £anking intron sequence (lower
case italics), is presented, along with the predicted amino acid se-
quence. Potential myristolation sites are indicated by P.
Fig. 2. Northern blot. A Northern blot was performed as described
in Section 2 using a 32P-labeled fragment of exon 10. Northern blots
with exon 4 and 7/8/9 are from the literature [19]. The same source
and amount of RNA were used for all three Northern blots, which
were run on a single gel. Film exposure times did vary.
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than that of MOR-1E (9.74) and MOR-1C (7.03). The new
sequence contained no putative protein kinase C or casein
phosphorylation sites, but there were four potential myristo-
lation sites, raising the possibility of an association of the C-
terminal tail with the membrane.
Cells stably expressing MOR-1F bound the mu opioid
[3H]DAMGO quite potently, with an a⁄nity similar to the
other MOR-1 variants (Table 1) [19]. Competition studies
also revealed a selectivity pattern consistent with a mu opioid
receptor. Although mu opioids such as morphine, DAMGO,
the endomorphins, L-endorphin and naloxone all competed
binding quite potently, the delta-selective opioid DPDPE
and the kappa1-selective compound U50,488H were both in-
active at high concentrations (Table 1). Dynorphin A and
DSLET revealed weaker a⁄nities for MOR-1F than any of
the other variants tested.
To assess the importance of MOR-1F in mu opioid analge-
sia, we next treated groups of mice with an antisense oligo-
deoxynucleotide targeting exon 10 (Fig. 4). Prior studies with
other exons had indicated that these probes typically blocked
either morphine or M6G analgesia [9,16,19]. The antisense
probe based upon exon 10 was inactive against M6G analge-
sia and it had only a modest e¡ect against morphine when
compared to the saline controls. This decrease was marginally
signi¢cant and less than that seen in antisense mapping studies
looking at exons 4, 6, 7, 8 and 9. Thus, these ¢ndings suggest
that mu receptors containing exon 10 have, at most, a limited
role in morphine analgesia.
The identi¢cation of the new exon illustrates a continuously
increasing complexity of the MOR-1 gene. There are now
seven variants di¡ering only at the tip of the C-terminus.
The roles of all these variants remain unknown. They all
bind morphine and other mu opioids quite potently while
showing no appreciable a⁄nity for selective delta and kappa
ligands. Although the endogenous opioid peptides do show
subtle binding di¡erences among the variants, their signi¢-
cance is not clear. The expression of the variants varies among
brain regions and even within cells [19]. For example, the
striatum has high levels of MOR-1 and little detectable
Table 1
Selectivity of MOR-1 splice variants in transfected CHO cell membranes
Values (nM)
MOR-1 MOR-1C MOR-1D MOR-1E MOR-1F
Saturation studies (KD)
[3H]DAMGO 1.75 þ 0.44 0.57 þ 0.14 0.35 þ 0.07 0.74 þ 0.11 1.04 þ 0.04
Competition studies (Ki)
Morphine 5.3 þ 2.0 2.4 þ 0.6 1.5 þ 0.2 2.3 þ 0.4 2.9 þ 0.5
M6G 5.2 þ 1.8 4.1 þ 1.2 4.8 þ 0.8 5.6 þ 0.7 9.6 þ 0.8
DAMGO 1.8 þ 0.5 0.9 þ 0.2 0.7 þ 0.1 1.2 þ 0.5 1.1 þ 0.2
DADLE 2.1 þ 0.3 3.2 þ 1.9 1.3 þ 0.4 2.5 þ 0.7 5.3 þ 0.8
DSLET 12.5 þ 3.6 8.1 þ 1.2 3.6 þ 0.6 6.7 þ 1.4 14.3 þ 1.8
Naloxone 4.3 þ 0.9 2.8 þ 0.8 0.9 þ 0.1 2.8 þ 1.4 2.1 þ 0.5
Endomorphin 1 2.1 þ 0.8 1.4 þ 0.4 1.8 þ 0.3 2.4 þ 0.1 2.9 þ 0.5
Endomorphin 2 4.2 þ 1.8 1.6 þ 0.2 2.0 þ 0.3 4.4 þ 0.8 4.1 þ 1.3
L-Endorphin 10.8 þ 2.9 5.8 þ 0.5 1.7 þ 0.4 5.0 þ 1.2 6.0 þ 1.6
Dynorphin A 10.9 þ 0.5 5.6 þ 0.8 2.2 þ 0.8 8.9 þ 1.1 12.1 þ 1.0
U50,488H s 500 s 500 s 500 s 500 s 500
DPDPE s 500 s 500 s 500 s 500 s 500
MOR-1F was stably expressed in CHO cells and a clone with high levels of expression (Bmax = 1.69 þ 0.35 pmol/mg protein) was selected for
further studies. Saturation studies with MOR-1F were performed with [3H]DAMGO (0.2 to 4 nM) and the KD and Bmax values determined by
non-linear regression analysis. Results are the mean þ S.E.M. of at least three independent determinations. The KD values for MOR-1, MOR-
1A, MOR-1B and MOR-1C are from the literature [19].
Competition studies were performed against [3H]DAMGO (1 nM) using at least three concentrations of the indicated ligand with the same sta-
ble MOR-1F clone. IC50 values were calculated by non-linear regression analysis (Prism, Graphpad software) and converted to Ki values as pre-
viously reported [25,26]. Results are the means þ S.E.M. of at least three independent replications. Values for MOR-1, MOR-1C, MOR-1D and
MOR-1E are from the literature [19].
Fig. 4. Antisense mapping exon 10. An antisense oligodeoxynucleo-
tide primer (10 Wg, i.c.v.) targetting exon 10 (5P-CTTGCTGCCT TC
GTAAGGACCTGG-3P), a mismatch control (5P-CTTGTCGCT-
CTCTGAAGAGCCTGG-3P) or saline were administered to groups
of mice (nv 25) on days 1, 3 and 5 and analgesia assessed with ei-
ther morphine or M6G on the day after the last treatment. Signi¢-
cance was determined by Fisher exact test.
Fig. 3. Regional distribution of the MOR-1 and MOR-1F mRNA.
Total RNA was isolated from the indicated brain regions and sub-
jected to RT-PCR, as described in Section 2. RNA loading was as-
sessed with parallel reactions with a pair of L2-microglobulin prim-
ers, as described in Section 2.
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MOR-1C [23]. Clearly, function is dependent upon the region
of the brain expressing the variant, but the importance of the
C-terminus in coupling to G-proteins raises questions about
transduction mechanisms. These variants also might a¡ect
associations with other membrane-associated proteins, includ-
ing dimerization with other opioid receptors [24]. Di¡erences
in putative phosphorylation sites may play a role in receptor
regulation. However, all these possibilities remain speculative
and remain to be explored in greater detail.
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